Several other research firms have also issued reports on MZOR. Barclays PLC boosted their target price on Mazor Robotics from $24.00 to $28.00 and gave the stock an overweight rating in a research report on Tuesday, October 11th. Zacks Investment Research upgraded Mazor Robotics from a sell rating to a hold rating and set a $22.00 target price for the company in a research report on Tuesday, July 19th. B. Riley initiated coverage on Mazor Robotics in a research report on Tuesday, October 11th. They set a neutral rating and a $25.00 target price for the company. Finally, Standpoint Research initiated coverage on Mazor Robotics in a research report on Friday, July 8th. They set a buy rating and a $30.00 target price for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $26.25.
Mazor Robotics (NASDAQ:MZOR) opened at 23.75 on Wednesday. The company’s market cap is $514.73 million. The company’s 50-day moving average is $23.40 and its 200 day moving average is $18.37. Mazor Robotics has a 12 month low of $8.31 and a 12 month high of $26.55.
Mazor Robotics (NASDAQ:MZOR) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The firm earned $8.30 million during the quarter, compared to analysts’ expectations of $8.51 million. Mazor Robotics had a negative return on equity of 42.30% and a negative net margin of 60.75%. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.05) EPS. Equities analysts forecast that Mazor Robotics will post ($0.71) earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the stock. EAM Investors LLC acquired a new position in shares of Mazor Robotics during the second quarter valued at about $2,348,000. Iguana Healthcare Management LLC raised its position in shares of Mazor Robotics by 384.6% in the first quarter. Iguana Healthcare Management LLC now owns 121,151 shares of the company’s stock valued at $1,507,000 after buying an additional 96,151 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new position in shares of Mazor Robotics during the second quarter valued at about $1,079,000. Menta Capital LLC raised its position in shares of Mazor Robotics by 81.9% in the first quarter. Menta Capital LLC now owns 37,482 shares of the company’s stock valued at $466,000 after buying an additional 16,879 shares in the last quarter. Finally, Cookson Peirce & Co. Inc. acquired a new position in shares of Mazor Robotics during the second quarter valued at about $192,000. Institutional investors and hedge funds own 18.72% of the company’s stock.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.